The monoclonal antibody given to infants to prevent severe RSV appears to deliver a second benefit that was not its design goal: fewer antibiotic prescriptions. Researchers at the Children's Hospital of Philadelphia found that infants who received nirsevimab had 14.4 percent fewer antibiotic prescriptions for outpatient acute respiratory tract infections than those who did not.
The reductions were larger for more specific conditions. Antibiotic prescribing for outpatient bronchiolitis fell 40.3 percent, and antibiotic prescribing during RSV-related hospitalizations fell 69.4 percent, though the latter estimate had a very wide confidence interval ranging from 4.8 percent to 90.1 percent. The findings were published in Clinical Infectious Diseases.
For parents, the relevance is straightforward. Antibiotics do nothing against a virus, yet viral respiratory illness in infants is one of the most common situations in which they are prescribed anyway, and every unnecessary course carries a side-effect risk.
The Prescribing Problem This Addresses
RSV is the most common cause of hospitalization in children under one year old and is estimated to account for roughly one in three hospitalizations for acute respiratory tract infection. It is also a common trigger for antibiotic use.
About half of children hospitalized with RSV and nearly a third seen in outpatient clinics with RSV receive an antibiotic. Some of that reflects genuine bacterial complications, since RSV can mimic or lead to ear infections or pneumonia, and some reflects diagnostic uncertainty.
The study's reasoning was that preventing the viral infection would remove the visits at which that decision is made. That is an indirect route to stewardship, and it does not require changing how any clinician prescribes. An independent research summary framed the result the same way.
The Design and Its Limits
Researchers analyzed electronic health record data from 32 practices in the CHOP Primary Care Network, covering infants under 8 months who had a primary care visit within 14 days of birth. Among 15,341 eligible infants, with an average age of 3.5 months and 48.7 percent female, 7,413 received nirsevimab.
This was not a randomized trial. Investigators used a method called target trial emulation, which structures observational data to mimic the design of a randomized study. The authors noted that a randomized trial testing antibiotic prescribing as an endpoint would not be practical or ethical given that nirsevimab is already recommended.
The two groups were similar on measured characteristics, including gestational age, complex chronic conditions, and insurance coverage. That strengthens the comparison but does not rule out unmeasured differences, such as how quickly families brought a sick infant to care.
The results also come from a single network spanning practices in New Jersey and Pennsylvania. Prescribing culture varies between health systems and regions, so the effect size elsewhere could differ. The authors concluded that nirsevimab given in primary care reduced antibiotic use for respiratory infections in both ambulatory and inpatient settings.
Families Weighing the Fall Immunization Schedule
Nirsevimab received FDA approval in July 2023 and is recommended for infants under 8 months entering or born during their first RSV season, and for some children aged 8 to 19 months at increased risk. RSV season in this network was defined as October through March.
For a parent deciding whether to accept the shot at a well-child visit, this study adds a consideration that sits alongside the primary one. The main reason remains the prevention of severe RSV illness and hospitalization, which earlier randomized trials and real-world analyses have established.
The antibiotic finding is a secondary observation about prescribing patterns, not a new indication, and it is not a reason to take the product independent of its RSV benefit.
Access has been uneven since launch. Earlier research from the same institution documented disparities in nirsevimab uptake across the network, with 35 percent of eligible children receiving it in the first season and lower rates among infants who were publicly insured, Black or living in areas with lower childhood opportunity. Research from another pediatric network found similar patterns.
Practical Steps Before RSV Season
Parents of infants who will be under 8 months during the coming RSV season can ask their pediatrician whether nirsevimab is recommended for their child and whether the practice will stock it. Timing matters, since protection is intended to cover the season.
Families should also know that maternal RSV vaccination during pregnancy is an alternative pathway to infant protection, and infants whose mothers were vaccinated may not need nirsevimab. Infants with maternal RSV vaccination were excluded from this analysis. That decision belongs with the obstetric and pediatric teams.
Nirsevimab is covered under the Vaccines for Children program for eligible children, and most insurance plans cover recommended immunizations without cost-sharing. Families without coverage can ask their pediatric practice or local health department about program eligibility.
Signs that an infant with a respiratory illness needs prompt evaluation include difficulty breathing, rapid or labored breathing, pauses in breathing, poor feeding, fewer wet diapers, or a bluish tint around the lips. Those warrant urgent care regardless of immunization status.
The CDC publishes RSV immunization guidance for infants and young children, and the recommendations are reviewed each season.
Key Questions Answered
What did the study find? Infants who received nirsevimab had 14.4% fewer antibiotic prescriptions for outpatient respiratory infections, 40.3% fewer for outpatient bronchiolitis, and 69.4% fewer during RSV-related hospitalizations.
Is nirsevimab an antibiotic? No. It is a monoclonal antibody that provides direct, short-term protection against RSV. The reduction in antibiotic use is an indirect effect of preventing the viral illness.
Was this a clinical trial? No. It was an observational analysis using target trial emulation, a method that structures existing health record data to approximate a randomized comparison.
What are the main limitations? The data come from one pediatric network; unmeasured differences between families cannot be fully ruled out; and the hospitalization estimate rested on a very wide confidence interval.
Who is nirsevimab recommended for? Infants under 8 months entering or born during their first RSV season, and some children aged 8 to 19 months, are at increased risk of entering a second season.
Does this change the reason to give it? No. Preventing severe RSV illness and hospitalization remains the primary purpose. The antibiotic finding is a secondary benefit.
When should a parent seek urgent care? Difficulty or rapid breathing, pauses in breathing, poor feeding, reduced wet diapers, or bluish coloring around the lips all require immediate
